Clinical use of pre-emptive pharmacogenetic programmes

Affiliations

¹ INUBE Extremadura Biosanitary University Research Institute, E 06080 Badajoz, Spain; University of Extremadura Medical School, E 06080 Badajoz, Spain.
² INUBE Extremadura Biosanitary University Research Institute, E 06080 Badajoz, Spain; University of Extremadura Medical School, E 06080 Badajoz, Spain; CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: allerena@unex.es.

Comment

Eva Peñas-LLedó et al. Lancet. 2023.

. 2023 Feb 4;401(10374):320-321.

doi: 10.1016/S0140-6736(22)02461-8.

¹ INUBE Extremadura Biosanitary University Research Institute, E 06080 Badajoz, Spain; University of Extremadura Medical School, E 06080 Badajoz, Spain.
² INUBE Extremadura Biosanitary University Research Institute, E 06080 Badajoz, Spain; University of Extremadura Medical School, E 06080 Badajoz, Spain; CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: allerena@unex.es.

No abstract available

Conflict of interest statement

We declare no competing interests.

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.